Publications by authors named "Lincy S Lai"
J Manag Care Spec Pharm
January 2021
Article Synopsis
- The study compares two methods for treating patients with rheumatoid arthritis (RA) who stop using tumor necrosis factor inhibitors (TNFi): cycling to another TNFi (like adalimumab) and switching to a different drug (like abatacept).
- Using a cost-utility microsimulation model, the research found that switching to abatacept after first TNFi failure had a higher cost over 10 years but provided a slight quality-of-life benefit compared to adalimumab.
- Results indicated that switching to abatacept is likely to be cost-effective, with an 80.6% chance of being a good value at a willingness-to-pay threshold of $100,000 per quality
